Jacqualyn A. Fouse - 08 Apr 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse
Issuer symbol
AGIO
Transactions as of
08 Apr 2023
Net transactions value
-$101,007
Form type
4
Filing time
12 Apr 2023, 16:17:27 UTC
Previous filing
16 Feb 2023
Next filing
15 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +15,933 +19% $0.000000 98,515 08 Apr 2023 Direct
transaction AGIO Common stock Tax liability $101,007 -4,731 -4.8% $21.35 93,784 12 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Options Exercise $0 -15,933 -33% $0.000000 31,867 08 Apr 2023 Common stock 15,933 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2 The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.